Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.

  • Revenue in EUR (TTM)6.81bn
  • Net income in EUR151.80m
  • Incorporated1987
  • Employees23.74k
  • Location
    Grifols SAParque Empresarial Can Sant JoanAvinguda de la Generalitat, 152-158SANT CUGAT DEL VALLES 08174SpainESP
  • Phone+34 935710000
  • Fax+34 935710267
  • Websitehttps://www.grifols.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Orion Oyj1.43bn331.80m6.22bn3.82k18.706.7015.894.352.362.3610.166.580.95931.536.94393,502.2022.2519.4728.2524.1659.8959.3823.1920.711.41143.690.217491.83-11.264.01-37.971.8911.821.55
Financiere de Tubize SA0.00183.85m6.43bn--34.963.4034.96--4.134.130.0042.450.00------9.647.049.857.24------145.70----0.016120.94----3.50-20.93--11.61
Elanco Animal Health Inc4.19bn192.97m6.57bn9.30k34.551.077.991.570.40870.40878.9913.200.32241.215.09478,924.701.48-3.271.64-3.6554.6954.284.60-11.531.310.98830.4005--0.1367.57-1,478.21--2.74--
Grifols SA6.81bn151.80m6.77bn23.74k48.001.2910.350.99340.22130.22139.798.230.31151.219.02286,836.401.002.391.343.0538.5140.263.217.540.80051.580.5620--8.718.00-71.52-36.98-0.8127--
Abbott India Ltd676.62m143.29m6.78bn3.81k47.3017.2644.7910.02604.57604.572,854.721,657.051.275.3215.7115,904,690.0026.8220.9236.9728.5945.0944.2021.1817.261.71131.360.016977.069.359.7226.5221.6831.0852.32
Halozyme Therapeutics, Inc.891.75m369.43m7.14bn373.0019.7316.7516.008.013.023.027.303.560.47241.303.772,539,826.0019.5718.2220.7321.9782.0979.0541.4339.369.15--0.76870.0025.6240.4339.31--26.82--
Alkem Laboratories Ltd1.42bn229.13m7.34bn17.28k32.03--27.635.17171.81171.811,064.87--------7,369,150.00--11.88--17.5062.2159.2616.2913.94--9.12--29.829.2111.4882.4718.75-13.3020.11
Jazz Pharmaceuticals PLC3.76bn435.98m7.43bn2.80k17.991.857.071.987.107.1060.2769.010.34040.73715.911,425,969.003.971.484.461.6289.3788.7911.654.263.742.820.59440.004.7815.19285.14-1.49-20.04--
Innovent Biologics Inc972.70m-167.15m7.47bn5.26k--4.59--7.68-0.8656-0.86565.018.230.39051.326.251,649,722.00-6.71-13.06-8.22-15.8582.4484.51-17.18-43.442.51-6.910.2123--36.21265.7952.83--34.60--
CSPC Pharmaceutical Group Ltd4.13bn773.10m7.56bn20.30k9.901.6916.101.830.53920.53922.883.160.69143.014.991,451,858.0013.2516.0817.6421.5771.3872.9519.1619.632.2240.860.010635.511.6612.16-3.5813.77-2.5825.33
Data as of Nov 13 2024. Currency figures normalised to Grifols SA's reporting currency: Euro EUR

Institutional shareholders

26.74%Per cent of shares held by top holders
HolderShares% Held
Capital International Ltd.as of 03 Oct 202417.31m4.06%
DWS Investment GmbHas of 10 Jun 202413.78m3.23%
Capital Research & Management Co. (World Investors)as of 18 Sep 202413.57m3.19%
Flat Footed LLCas of 13 Aug 202413.34m3.13%
Hardman Johnston Global Advisors LLCas of 30 Sep 202413.19m3.10%
Norges Bank Investment Managementas of 30 Jun 20249.13m2.14%
The Vanguard Group, Inc.as of 30 Sep 20249.02m2.12%
Mason Capital Management LLCas of 18 Sep 20249.01m2.11%
BNP Paribas Asset Management Europe SASas of 13 Mar 20248.38m1.97%
BlackRock Fund Advisorsas of 03 Oct 20247.26m1.70%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.